QQ客服 官方微博 反馈留言

	Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial
	Hu, Xing-Sheng; Han, Xiao-Hong; Yang, Sheng; Li, Ning; Wang, Lin; Song, Yuan-Yuan; Mu, Hua; Shi, Yuan-Kai
	2019
卷号	11页码:4449-4459
关键词	simotinib EGFR non-small cell lung cancer toxicity pharmacokinetics
ISSN号	1179-1322
DOI	10.2147/CMAR.S189626
URL标识	查看原文
收录类别	SCIE ; PUBMED
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6340953
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Hu, Xing-Sheng,Han, Xiao-Hong,Yang, Sheng,et al. Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial[J],2019,11:4449-4459.
APA	Hu, Xing-Sheng.,Han, Xiao-Hong.,Yang, Sheng.,Li, Ning.,Wang, Lin.,...&Shi, Yuan-Kai.(2019).Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial.,11,4449-4459.
MLA	Hu, Xing-Sheng,et al."Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial".11(2019):4449-4459.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。